Skip to main content

Advertisement

Table 1 Baseline patient characteristics (n = 31)

From: A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

Characteristics N (%)
Age (years)
 Median 69
 Range, interquartile range (37–86, 61–73)
Gender
 Male 21 (68)
 Female 10 (32)
ECOG performance status
 0 13 (42)
 1 16 (52)
 2 2 (6)
Primary tumor location
 Colon 25 (81)
 Rectum 6 (19)
Primary resected
 Yes 26 (84)
 No 5 (16)
No of metastatic site,
 1 10 (32)
 2 9 (29)
  ≥ 3 12 (39)
Metastatic sites
 Liver 22 (71)
 Lung 17 (55)
 Lymph nodes 13 (42)
 Peritoneum 9 (29)
 Other 4 (13)
KRAS mutation
 Yes 13 (37)
 No 18 (63)
BRAF mutation
 Yes 2 (6)
 No 26 (84)
 Unknown 3 (10)
Number of lines prior therapy
 2 8 (19)
 3 16 (59)
  ≥ 4 7 (22)
Median CEA level ng/ml (range, interquartile range) 116 (0–42,230, 31–350)
Median CA19-9 level ng/ml (range, interquartile range) 222 (5–9820, 38–965)
  1. ECOG Eastern Cooperative Oncology Group, CEA serum carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9